Matsushima Yuko, Kawabata Ryohei, Imamura Hiroshi, Kishimoto Tomono, Hachino Yoshimi, Yasui Yukako, Fujino Misako, Fujii Chika, Fukunaga Mutsumi, Ohzato Hiroki, Furukawa Hiroshi
Dept. of Surgery, Sakai Municipal Hospital.
Gan To Kagaku Ryoho. 2012 Jun;39(6):911-4.
We investigated the efficacy of gastrojejunostomy followed by S-1-based chemotherapy for unresectable gastric cancer with pyloric stenosis. We performed gastrojejunostomy and S-1-based chemotherapy in 14 unresectable gastric cancer patients with gastric outlet obstructions between April 2006 and June 2010. Although there were two complications after surgery, no treatment-related deaths were observed. The response rate of the S-1-based chemotherapy was 41.7%, and the median survival after surgery was 12.3 months. All patients were tolerating a regular diet and a significant improvement in oral intake lasted for at least 6 months. In conclusion, gastrojejunostomy followed by chemotherapy with S-1 appears to be an effective treatment modality for unresectable gastric cancer with pyloric stenosis. It enables us to practice S-1-based standard chemotherapy for advanced gastric cancer and improve the quality of life of patients.
我们研究了胃空肠吻合术联合基于S-1的化疗对伴有幽门狭窄的不可切除胃癌的疗效。2006年4月至2010年6月期间,我们对14例伴有胃出口梗阻的不可切除胃癌患者实施了胃空肠吻合术及基于S-1的化疗。尽管术后出现了2例并发症,但未观察到与治疗相关的死亡病例。基于S-1的化疗的有效率为41.7%,术后中位生存期为12.3个月。所有患者均能耐受正常饮食,且口服摄入量显著改善持续至少6个月。总之,胃空肠吻合术联合S-1化疗似乎是治疗伴有幽门狭窄的不可切除胃癌的一种有效治疗方式。它使我们能够对晚期胃癌实施基于S-1的标准化化疗,并提高患者的生活质量。